The D+Q combination has been tested in clinical trials and the results show that D+Q significantly improve the physiological functions in idiopathic pulmonary fibrosis (IPF) patients (Justice et al., 2019) and can effectively eliminate p16INK4a-positive cells, reduce the activity of SA-β-gal, and attenuate the release of inflammatory factors in patients with diabetic nephropathy (Hickson et al., 2019). This evidence concerns the gene CDKN2A and idiopathic pulmonary fibrosis.